Clinical Trials

JBCRG-06

Evaluation of the response rate, the pathological response and the safety of neoadjuvant Letrozole for postmenopausal women with hormone receptor positive, operable and primary breast which confirmed SD or PD in prior anthracycline-containing chemotherapy.

Status
Study Closed

Objectives

Subjects

Endpoints
Primary endpoint: Response rate, Secondary endpoints: Pathological CR rate, Breast Conserving Surgery rate, Safety, Disease-free survival and Overall survival

Trial Period
September 2007 - September 2015 (Registration: 3 years, Follow-up study: 5 years)

Lead Principal Investigator
Masahiro Kashiwaba (Department of Surgery, Iwate Medical University)

Target Sample Size
45

Regimen
Letrozole 12(-18)w

Source of Funding
Japan Breast Cancer Research Group (JBCRG)

Conference Presentation

Articles and Publications

UMIN-ID
UMIN000001325

jRCT

Memo

COI Disclosure

Previous PageClinical TrialsNext Page